Keyword Suggestions

Results
 
 
Account Login
 
Username
 
 
 
Password
 
 
 
 
 

Library Navigation
 
 

Browse Conferences
 
 
 
66 Results Found, Showing 1 - 50
Sort By:
View:
Filter By:
Date/Time
Conference
Keyword
My Content
Start Date/Time:
End Date/Time:
 
Go
 
Conference
 
Keywords:
Click here to clear this filter
 
 
Go
Show only the content that I own
 
 
October 17, 2009 - Saturday
 
rating
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
23.35% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
23.35% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
49.30% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
49.30% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA05 - HspC90 as Emerging Therapy in HER2 + Breast Cancer 
Relevancy:
61.17% 
 
Date/Time:
October 17, 2009   10:45am - 11:20am
 
Length:
17m 21s - 57 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Shanu Modi, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA05 - HspC90 as Emerging Therapy in HER2 + Breast Cancer 
Relevancy:
61.17% 
 
Date/Time:
October 17, 2009   10:45am - 11:20am
 
Length:
17m 21s - 57 Slides  
 
Speaker:
Shanu Modi, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
88.93% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
88.93% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
68.28% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
68.28% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA09 - New Molecular Imaging Agents Provide a Better Look at Cancer 
Relevancy:
100.00% 
 
Date/Time:
October 17, 2009   2:10pm - 2:45pm
 
Length:
25m 15s - 28 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Jerry Collins, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA09 - New Molecular Imaging Agents Provide a Better Look at Cancer 
Relevancy:
100.00% 
 
Date/Time:
October 17, 2009   2:10pm - 2:45pm
 
Length:
25m 15s - 28 Slides  
 
Speaker:
Jerry Collins, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
70.58% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
70.58% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 24, 2009 - Thursday
 
rating
HM101 - Treatment of Newly Diagnosed Myeloma in Non-transplant Candidates 
Relevancy:
54.04% 
 
Date/Time:
September 24, 2009   1:00pm - 1:30pm
 
Length:
18m 27s - 28 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Sagar Lonial, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
U102 - The Risks and Benefits of Chemoprevention in Prostate Cancer 
Relevancy:
23.33% 
 
Date/Time:
September 24, 2009   1:35pm - 2:05pm
 
Length:
30m 16s - 37 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Andrew J. Stephenson, MD, FRCSC (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM102 - Treatment of Newly Diagnosed Transplant Candidates 
Relevancy:
37.10% 
 
Date/Time:
September 24, 2009   1:35pm - 2:05pm
 
Length:
22m 40s - 32 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Muzzafar H. Qazilbash (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM103 - Treatment of Relapsed and Refractory Myeloma 
Relevancy:
81.52% 
 
Date/Time:
September 24, 2009   2:10pm - 2:40pm
 
Length:
22m 13s - 37 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Sagar Lonial, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM104 - Future Directions in Myeloma 
Relevancy:
63.08% 
 
Date/Time:
September 24, 2009   2:45pm - 3:15pm
 
Length:
40m 52s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Kenneth Anderson (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U105 - How Successful is Radiation Therapy for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer? Can it be Used for Superficial Bladder Cancer? 
Relevancy:
49.95% 
 
Date/Time:
September 24, 2009   3:30pm - 4:00pm
 
Length:
37m 45s - 56 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Howard Sandler, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HN101 - Concomitant Chemoradiotherapy 
Relevancy:
69.74% 
 
Date/Time:
September 24, 2009   3:30pm - 4:00pm
 
Length:
38m 18s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ezra EW Cohen, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
S101 - What is the Optimal Approach to Primary Sarcomas? 
Relevancy:
23.04% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
27m 24s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robert G. Maki, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U106 - New Targets, New Agents, New Trials for Bladder Cancer 
Relevancy:
71.55% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
28m 15s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Dean F. Bajorin, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM106 - JAK2 Mutations in MPD: A Worthy Therapeutic Target? 
Relevancy:
57.50% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
48m 47s - 46 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Olatoyosi Odenike, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HN104 - Induction Chemotherapy 
Relevancy:
97.43% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
14m 09s - 25 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ezra EW Cohen, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
S102 - Moving Molecular Pathways to New Diagnostic Categories and New Therapeutic Strategies 
Relevancy:
49.79% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
24m 51s - 33 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
William Tap, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM107 - Management of Iron Overload in Hematological Malignancies: Should We Chelate Patients with MDS? 
Relevancy:
35.57% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
20m 06s - 36 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mikkael A. Sekeres, MD, MS (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
S103 - Current Best Practices in the Multidisciplinary Management of GIST 
Relevancy:
76.81% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 57s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robert G. Maki, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U108 - What is the Standard of Care for Metastatic Renal Cell Carcinoma: First-line, Second-line? 
Relevancy:
58.27% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 35s - 56 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Dean F. Bajorin, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 25, 2009 - Friday
 
B201 - Neoadjuvant Therapy for Breast Cancer: Lessons Learned and New Directions with Targeted Therapeutics 
Relevancy:
53.77% 
 
Date/Time:
September 25, 2009   8:50am - 9:20am
 
Length:
25m 58s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Laura J. Esserman, MD, MBA (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM201 - Aggressive Lymphoma: Management in 2009 
Relevancy:
64.08% 
 
Date/Time:
September 25, 2009   8:50am - 9:20am
 
Length:
30m 44s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Jonathan W. Friedberg, MD, MMSC (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B202 - New Directions in the Treatment of 'Triple Negative' Breast Cancer 
Relevancy:
66.61% 
 
Date/Time:
September 25, 2009   9:25am - 9:55am
 
Length:
31m 46s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Lee S. Schwartzberg, MD, FACP (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM202 - Indolent Lymphomas: Issues in Clinical Practice 
Relevancy:
38.12% 
 
Date/Time:
September 25, 2009   9:25am - 9:55am
 
Length:
28m 35s - 61 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Michael L. Grossbard, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY203 - Debate: All Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening 
Relevancy:
19.22% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
41m 26s - 51 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Beth Y. Karlan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM203 - Mantle Cell Lymphoma: How to Select the Best Treatment 
Relevancy:
64.31% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
26m 45s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mitchell R. Smith, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B204 - Adjuvant Chemotherapy for Breast Cancer: Are Anthracyclines Out? 
Relevancy:
55.45% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
32m 37s - 28 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Julie R. Gralow, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY204 - Evidence-Based Management of Newly Diagnosed Ovarian Carcinoma 
Relevancy:
20.18% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
34m 08s - 62 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
J. Tate Thigpen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON204 - GI Cancers: Top Ten Breakthroughs 2008-2009 - A Literature Review 
Relevancy:
86.84% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
27m 57s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Shannon B. Holloway (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON205 - Update on Wound Care for Cancer Patients 
Relevancy:
39.04% 
 
Date/Time:
September 25, 2009   2:40pm - 3:10pm
 
Length:
29m 26s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robin Gemmill, MSN, RN, CNS (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
B206 - Management of Brain Metastases: New Treatment Modalities 
Relevancy:
46.98% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
33m 45s - 57 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Michelle Melisko, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY206 - A Rational Approach to the Use of Systemic Therapy in Recurrent or Persistent Ovarian Carcinoma 
Relevancy:
66.22% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
36m 03s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Thomas Herzog, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM206 - How I Manage Relapsed NHL - What and When 
Relevancy:
33.48% 
 
Date/Time:
September 25, 2009   4:05pm - 4:35pm
 
Length:
29m 35s - 47 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
David G. Maloney, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B207 - Update on New Treatments for HER2 
Relevancy:
64.94% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
37m 06s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Hope S. Rugo, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY207 - Debate: Therapy for the Patient with Platinum-Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay 
Relevancy:
14.54% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
25m 13s - 76 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Bradley J. Monk, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM207 - Debate: There is Still a Role for Observation in Follicular Lymphoma 
Relevancy:
79.28% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
36m 21s - 34 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Sandra J. Horning, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON207 - Sexuality and Cancer 
Relevancy:
23.26% 
 
Date/Time:
September 25, 2009   4:40pm - 5:10pm
 
Length:
34m 31s - 36 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Kate Tierney, RN, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 26, 2009 - Saturday
 
HM301 - CLL Treatment: Do Pre-treatment Characteristics Guide Current Treatment Choices? 
Relevancy:
40.06% 
 
Date/Time:
September 26, 2009   8:15am - 8:45am
 
Length:
22m 28s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Neil E. Kay, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM302 - CLL Treatment: What Happens after Relapse from Front-line Therapy? 
Relevancy:
55.98% 
 
Date/Time:
September 26, 2009   8:50am - 9:20am
 
Length:
25m 17s - 38 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Neil E. Kay, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
L303 - Current Status of the Neoadjuvant and Adjuvant Chemotherapy of Lung Cancer 
Relevancy:
55.21% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
31m 17s - 48 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Scott Gettinger, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GI303 - Hepatocellular Carcinoma: New Trends and Contemporary Management 
Relevancy:
37.43% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
35m 09s - 59 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Andrew X. Zhu, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
66 Results Found, Showing 1 - 50
Previous Page |   Go To Page:   | Next Page